Although the immuno-oncology (I-O) field is still in its infancy, the industry's fascination with the technology continues to soar with investments and partnerships in the space being announced almost weekly as biopharma companies look to add promising cancer therapeutics to their pipelines. With the plethora of deals inked last year, the question becomes, Can this pace for I-O assets be maintained given the fact that immuno-oncology continues to attract many players? Read More
